Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXV94M)

• Drug Name: Inclacumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DMXV94M

Molecule-Related Drug Atlas

Drug(s) Targeting P-selectin (SELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizanlizumab	DMAHOVJ	Vaso-occlusive crisis	BE2Y	Approved	[3]
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[4]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[5]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[6]
SelG1	DMTQ2K0	Vaso-occlusive crisis	BE2Y	Phase 2	[7]
RPSGL-Ig	DM0BFJ5	Delayed graft function	4B24.0	Phase 2	[8]
PSI-697	DM75FWO	Atherosclerosis	BD40	Phase 1	[9]
CDP-850	DMWHQM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[10]
CY-1787	DMWY2NT	Allergy	4A80-4A85	Discontinued in Phase 1	[11]
PURPUROGALLIN	DM63O4F	N. A.	N. A.	Terminated	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P-selectin (SELP)	TTE5VG0	LYAM3_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT05348915) An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial. U.S.National Institutes of Health.
• [2] Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428.
• [3] Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
• [4] Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
• [5] Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
• [6] Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
• [7] Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
• [8] rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
• [9] Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
• [10] WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
• [11] Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.